An observational study in Postoperative Pain, sponsored by Second Hospital of Shanxi Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Second Hospital of Shanxi Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies in Pain, Postoperative with a site in China — 79 open to participants now, 81 under way, 3 of them phase 3. Pain, Postoperative · China.
Among the 249 studies in Pain, Postoperative with a site in China, this one is the 27th largest by planned enrollment of the 43 observational ones that give a count, is one of 29 that started in 2025, is one of 43 observational ones, reaches primary completion later than 40 of the 80 other live ones, and was the 246th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →79 of the 249 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–80
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–90
The First People's Hospital of Lianyungang · Sites in China
Ages 18–85
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 13 · Phase 4 67
First in 2004; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 216 is above the median of 102 across 685 observational studies indexed under Pain, Postoperative.
Median enrollment 131 across the 206 interventional studies, 350 across the 43 observational. Of the 121 that completed or were terminated, 6 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 249 have an industry lead sponsor. The 10 most frequent:
Second Hospital of Shanxi Medical University is the lead sponsor of 28 studies on the registry; 16 are open to participants now.
Second Hospital of Shanxi Medical University has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
22 of the studies in Pain, Postoperative with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07331441Jun ZhangExternal Oblique Intercostal Plane Block for Postoperative Analgesia After Major Upper Abdominal Surgery | 2026-11-25 |
| NCT07412223Xiangya Hospital of Central South UniversityEffect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery | 2026-12-01 |
| NCT07653932Tongji HospitalPerioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery | 2026-12-31 |
| NCT07810413The First People's Hospital of LianyungangAnrikefon Injection for Postoperative Analgesia in Thoracoscopic Lung Surgery: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Center Clinical Study | 2026-12-31 |
| NCT07519109CSPC Ouyi Pharmaceutical Co., Ltd.Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 249 studies in Pain, Postoperative with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study aims to determine the incidence and clinical characteristics of rebound-breakthrough pain after ultrasound-guided brachial plexus block in adult patients with type 2 diabetes mellitus. Adult patients undergoing elective upper-extremity surgery are divided into a type 2 diabetes group and a non-diabetic control group. Baseline clinical data and pain-related outcomes are collected after nerve block. This work may provide evidence for optimizing perioperative pain management for diabetic patients receiving brachial plexus block.
Background: Diabetes mellitus is a highly prevalent chronic disease worldwide. Diabetic peripheral neuropathy is one of its common complications, which may alter peripheral nerve function and pain perception. Brachial plexus block is widely used for upper-limb surgery. Rebound-breakthrough pain is a clinically important adverse event after peripheral nerve block, which worsens postoperative recovery and increases opioid consumption. The incidence and clinical features of this pain among patients with type 2 diabetes remain unclear.
This observational study enrolls adult patients undergoing elective upper-extremity surgery with ultrasound-guided brachial plexus block. Participants are separated into two groups: patients with type 2 diabetes mellitus and patients without diabetes. All patients receive routine clinical anesthesia with 0.375% ropivacaine for brachial plexus block without any experimental intervention. Pre-operative baseline information includes demographic data, glycosylated hemoglobin, diabetic history, and sensory threshold measurement. Post-block data including pain scores, onset and recovery time of sensory-motor block, patient-controlled analgesia usage and additional analgesic consumption are recorded.
The primary objective is to calculate the incidence of postoperative breakthrough-rebound pain. Secondary objectives cover pain severity, onset and duration of breakthrough pain, and perioperative analgesic consumption. Collected data will be summarized and analyzed to describe clinical characteristics associated with breakthrough pain.
Adult patients receiving ultrasound-guided brachial plexus block for elective upper-extremity surgery. Subjects are divided into two cohorts: patients with type 2 diabetes mellitus and non-diabetic patients. Routine clinical anesthesia management is adopted without experimental interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients diagnosed with type 2 diabetes mellitus undergoing elective upper-extremity surgery with ultrasound-guided brachial plexus block. All subjects receive routine clinical anesthesia with 0.375% ropivacaine without experimental intervention.
Adult non-diabetic patients undergoing elective upper-extremity surgery with ultrasound-guided brachial plexus block. All subjects receive routine clinical anesthesia with 0.375% ropivacaine without experimental intervention.
Incidence of postoperative rebound-breakthrough pain
Proportion of participants developing rebound-breakthrough pain within 48 hours after brachial plexus block.Rebound-breakthrough pain after peripheral nerve block is characterized by sudden severe pain (NRS ≥ 7) occurring within 24 hours after block resolution. It is typically burning in nature, may occur at rest or during movement, lasts more than 2 hours, and most frequently develops 12-24 hours postoperatively.
Time frame: Within 48 hours after brachial plexus block
Within 48 hours after brachial plexus block
Peak numerical rating scale (NRS, 0-10) score during each rebound-breakthrough pain episode. Higher score indicates more severe pain.
Time frame: Within 48 hours after block
Onset time of first rebound-breakthrough pain
Time interval from completion of brachial plexus block to the first occurrence of rebound-breakthrough pain.
Time frame: Within 48 hours after block
Frequency of rebound-breakthrough pain episodes
Total number of rebound-breakthrough pain episodes within 48 hours after brachial plexus block.
Time frame: Within 48 hours after block
Duration of each rebound-breakthrough pain episode
Duration of each rebound-breakthrough pain episode that occurs within 48 hours after brachial plexus block.
Time frame: Within 48 hours after block
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Hospital of Shanxi Medical University